In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

1. What is the term for a transplantation procedure in which cells or organs are transferred between individuals belonging to ...

Despite the promise, the therapy developed by Vertex Pharmaceuticals ... Unlike most of the body’s cells, embryonic stem ...

Vertex Pharma has made its name ... The therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose.

Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other ...

You have around 35 trillion red blood cells moving around your body at all times. Typically they are rounded and flexible. What happens when they aren’t?

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

A privately held clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, is pioneering messenger RNA (mRNA)-based medicines to transform how the human body prevents and ...

HOUSTON (AP) — Vertex Energy Inc. VTNR) on Thursday reported a loss of $53.8 million in its second quarter. The Houston-based company said it had a loss of 58 cents per share. HOUSTON ...